Key result
Among adults aged ≥50 years, injection site and systemic reactions were less frequent after a second mRNA COVID-19 booster than the first, and 94.8% of VAERS reports were nonserious.
Why the study?
Following FDA authorization of a second mRNA COVID-19 booster dose for adults aged 50 years and immunocompromised individuals, characterization of its safety was needed.
What is the safety profile of a second mRNA booster dose of COVID-19 vaccine in adults aged ≥50 years?
Observational (n=286,380)
Yes
What is the safety profile of a second mRNA booster dose of COVID-19 vaccine in adults aged ≥50 years?
A second mRNA COVID-19 booster dose in adults aged ≥50 years is associated with expected local and systemic reactions that are less frequent than after the first booster, with serious adverse events being uncommon.
Answers are grounded in this paper and cite their sources.
Supports second booster safety monitoring; leaves open long-term risks and effectiveness in expanded groups.
The Advisory Committee on Immunization Practices (ACIP) recommends that all persons aged 5 years receive 1 booster dose of a COVID-19 vaccine after completion of their primary series.* On March 29, 2022, the Food and Drug Administration (FDA) authorized a second mRNA booster dose 4 months after receipt of a first booster dose for adults aged 50 years and persons aged 12 years with moderate to severe immunocompromise (1,2). To characterize the safety of a second mRNA booster dose among persons aged 50 years, CDC reviewed adverse events and health impact assessments reported to v-safe and the Vaccine Adverse Event Reporting System (VAERS) after receipt of a second mRNA booster dose during March 29-July 10, 2022. V-safe is a voluntary smartphone-based U.S. active surveillance system that monitors adverse events occurring after COVID-19 vaccination. VAERS is a U.S. passive surveillance system for monitoring adverse events after vaccination, managed by CDC and FDA (3). During March 29-July 10, 2022, approximately 16.8 million persons in the United States aged 50 years received a fourth dose. Among 286,380 v-safe registrants aged 50 years who reported receiving a second booster of an mRNA vaccine, 86.9% received vaccines from the same manufacturer for all 4 doses (i.e., homologous vaccination). Among registrants who reported homologous vaccination, injection site and systemic reactions were less frequent after the second booster dose than after the first booster dose. VAERS received 8,515 reports of adverse events after second mRNA booster doses among adults aged 50 years, including 8,073 (94.8%) nonserious and 442 (5.1%) serious events. CDC recommends that health care providers and patients be advised that local and systemic reactions are expected after a second booster dose, and that serious adverse events are uncommon.
No takes yet. Share an insight, caveat, or question.
Hause et al. (2022) conducted an observational in COVID-19 vaccination (n=286,380). Second mRNA COVID-19 vaccine booster dose vs. First booster dose was evaluated on Adverse events (injection site and systemic reactions). Among adults aged ≥50 years, injection site and systemic reactions were less frequent after a second mRNA COVID-19 booster than the first, and 94.8% of VAERS reports were nonserious.
Synapse has enriched 10 related papers. Consider them for comparative context: